WHO Cannabis Risk Assessment — Global Health Policy and Rescheduling

Executive Summary

The World Health Organization published its first comprehensive reassessment of cannabis risks in a decade during August 2026, marking a pivotal moment in global drug policy. This evaluation by the WHO Expert Committee on Drug Dependence (ECDD) updates scientific understanding of cannabis harms, therapeutic potential, and scheduling recommendations under international drug control treaties. The assessment follows the organization's landmark 2019 recommendation to reschedule cannabis under the 1961 Single Convention on Narcotic Drugs, which member states narrowly approved in December 2020. The 2026 review incorporates emerging evidence on high-potency THC products, synthetic cannabinoids, medical applications of CBD and other cannabinoids, and public health outcomes from jurisdictions that have legalized adult-use cannabis since 2012. This reassessment carries significant implications for the 184 nations party to UN drug conventions, potentially influencing national reform efforts, pharmaceutical development pipelines, and the $32 billion global legal cannabis market. The WHO's findings will inform policy debates in countries considering legalization, shape FDA and DEA regulatory frameworks in the United States, and provide scientific grounding for ongoing international treaty discussions.

Why This Assessment Matters

The WHO cannabis risk assessment directly influences drug policy for nearly every nation on Earth through its impact on international treaty obligations. The organization's Expert Committee on Drug Dependence serves as the sole body authorized to make scientific recommendations on substance scheduling under the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. When the WHO recommends rescheduling or control changes, the UN Commission on Narcotic Drugs votes on implementation, creating binding obligations for member states. The 2026 assessment affects multiple stakeholder groups with competing interests. For the estimated 200 million global cannabis consumers, WHO findings influence criminalization policies, possession penalties, and access to legal supply chains. Medical patients in 40-plus countries with cannabis programs depend on WHO scientific validation to maintain therapeutic access and insurance coverage. The pharmaceutical industry watches closely as WHO conclusions on cannabinoid medicines affect regulatory pathways, patent strategies, and market exclusivity for drugs like Epidiolex, Sativex, and Marinol. Multi-state operators and licensed cannabis businesses face direct market consequences from international scheduling decisions. Canada's $4.8 billion legal market, Germany's emerging adult-use framework, and Thailand's medical cannabis industry all operate within constraints imposed by treaty compliance. A WHO recommendation to further deschedule cannabis or remove certain cannabinoids from international control could unlock cross-border commerce, pharmaceutical investment, and banking access currently restricted by treaty obligations. State and federal policymakers in the United States cite WHO assessments when debating reform legislation. The DEA referenced WHO recommendations in its August 2024 proposal to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act. The FDA relies on WHO reviews when evaluating investigational new drug applications for cannabinoid therapeutics. Public health agencies use WHO risk assessments to design prevention programs, treatment protocols, and harm reduction interventions.

Background and History: Two Decades of WHO Cannabis Reviews

The World Health Organization's evolving position on cannabis reflects a fundamental shift in scientific understanding that began with preliminary reviews in 2002 and culminated in the historic 2019 recommendations.

Early WHO Assessments (2002-2014)

The WHO Expert Committee on Drug Dependence conducted limited cannabis reviews in 2002 and 2006, focusing primarily on synthetic cannabinoids and specific pharmaceutical preparations. These early assessments maintained cannabis in Schedule I and Schedule IV of the 1961 Single Convention, the most restrictive categories reserved for substances with high abuse potential and no recognized medical value. The ECDD's 2002 report acknowledged therapeutic applications of THC-based medicines but concluded insufficient evidence existed to recommend rescheduling whole-plant cannabis. Between 2006 and 2014, mounting evidence from jurisdictions experimenting with medical cannabis programs prompted renewed scientific interest. Colorado and Washington became the first U.S. states to legalize adult-use cannabis in 2012, followed by Uruguay's national legalization in 2013. These policy experiments generated real-world data on public health outcomes, youth consumption patterns, and impaired driving rates that previous WHO reviews lacked.

The 2018 Pre-Review and Critical Review Process

In June 2018, the WHO ECDD conducted a pre-review of cannabis and cannabis-related substances, examining five categories: cannabis plant and resin, cannabis extracts and tinctures, delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), and pharmaceutical preparations containing cannabis derivatives. The committee found sufficient evidence to warrant a comprehensive critical review, the formal process required before making scheduling recommendations to the UN Commission on Narcotic Drugs. The November 2018 critical review in Geneva represented the most thorough scientific evaluation of cannabis in the WHO's history. The ECDD reviewed over 1,000 peer-reviewed studies, regulatory submissions from member states, and public health data from legal markets in North America. The committee heard testimony from researchers, patient advocates, and government officials representing diverse perspectives on cannabis policy.

The Historic 2019 Recommendations

On January 24, 2019, the WHO published six formal recommendations to the UN Commission on Narcotic Drugs. The most significant proposal called for deleting cannabis and cannabis resin from Schedule IV of the 1961 Single Convention while maintaining Schedule I placement. Schedule IV lists substances deemed particularly dangerous with no offsetting medical value, including heroin. The WHO concluded that cannabis does possess therapeutic applications, making Schedule IV placement scientifically unjustifiable. Additional recommendations addressed specific cannabinoids and preparations: - Delete THC and its stereoisomers from the 1971 Convention and add them to Schedule I of the 1961 Convention - Delete dronabinol (synthetic THC) from Schedule II of the 1971 Convention and add pharmaceutical preparations to Schedule III of the 1961 Convention - Add a footnote to Schedule I of the 1961 Convention clarifying that CBD preparations containing no more than 0.2% THC are not under international control - Add pharmaceutical preparations containing THC to Schedule III of the 1961 Convention - Delete extracts and tinctures of cannabis from Schedule I of the 1961 Single Convention The recommendations acknowledged cannabis dependence potential and acute intoxication risks while recognizing legitimate medical uses. The ECDD cited evidence supporting cannabis efficacy for chronic pain, chemotherapy-induced nausea, and multiple sclerosis spasticity.

The December 2020 UN Vote

After nearly two years of diplomatic negotiations, the UN Commission on Narcotic Drugs voted on the WHO recommendations on December 2, 2020. Member states approved the proposal to remove cannabis from Schedule IV by a narrow 27-25 margin, with one abstention. The vote represented the first time in 59 years that the international community formally acknowledged cannabis medical value. The United States voted in favor of rescheduling, marking a significant policy shift. The European Union split, with France and several Eastern European nations opposing the measure. Canada, Mexico, and most South American countries supported the change. China, Russia, and Pakistan voted against rescheduling. The Commission rejected the WHO's other five recommendations, maintaining existing controls on THC, pharmaceutical preparations, and cannabis extracts. This partial adoption created regulatory ambiguities that the 2026 assessment seeks to address.

Post-2020 Developments Driving the 2026 Review

Between 2020 and 2026, accelerating global cannabis reform created pressure for an updated WHO assessment. Germany launched adult-use legalization in April 2024, making it the largest European market. Thailand legalized medical cannabis in 2022, followed by recreational decriminalization. Malta, Luxembourg, and the Czech Republic implemented various legalization models. In the United States, 24 states operated adult-use programs by 2026, with federal rescheduling from Schedule I to Schedule III pending final DEA action. Scientific literature expanded dramatically, with over 3,000 peer-reviewed cannabis studies published between 2020 and 2026. Research focused on high-potency concentrate risks, cannabis use disorder treatment, cannabinoid hyperemesis syndrome, and therapeutic applications for PTSD, anxiety disorders, and opioid use disorder. The FDA approved additional cannabinoid medications beyond Epidiolex, including formulations for cancer pain and neurodegenerative diseases. Public health data from mature legal markets provided evidence on long-term outcomes. Colorado reported ten years of post-legalization data on youth consumption, traffic fatalities, and emergency department visits. Canada published five-year assessments of its national Cannabis Act implementation. This real-world evidence informed the WHO's 2026 reassessment methodology.

The 2026 Review Process and Scope

The WHO Expert Committee on Drug Dependence convened its 2026 cannabis reassessment during a week-long session in Geneva from August 19-23, 2026, examining evidence across seven priority areas. The ECDD's 2026 review focused on questions left unresolved by the 2019 recommendations and subsequent UN vote. The committee evaluated: **High-potency THC products**: Concentrates, vape cartridges, and edibles containing 70-99% THC now dominate legal markets in several U.S. states and Canada. The committee assessed dependence liability, acute psychiatric risks, and appropriate regulatory controls for products exceeding traditional cannabis potency ranges of 10-20% THC. **Synthetic cannabinoids**: The proliferation of synthetic cannabinoid receptor agonists sold as "spice" or "K2" created a public health crisis in multiple countries. The ECDD reviewed scheduling recommendations for novel synthetic cannabinoids and evaluated whether generic scheduling approaches could address rapidly evolving chemical variants. **Minor cannabinoids**: Emerging research on cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC), and delta-8-THC prompted evaluation of their pharmacology, abuse potential, and medical applications. The committee considered whether these compounds warrant separate scheduling or should remain uncontrolled. **Medical applications**: New clinical trial data on cannabis and cannabinoids for chronic pain, PTSD, cancer-related symptoms, and neurodegenerative diseases informed updated therapeutic assessments. The committee reviewed FDA and European Medicines Agency regulatory decisions on cannabinoid pharmaceuticals approved since 2020. **Public health outcomes**: The ECDD analyzed data from jurisdictions with 5-10 years of legal cannabis markets, examining youth consumption trends, impaired driving rates, cannabis use disorder prevalence, emergency department visits, and mental health outcomes. Comparative analysis between prohibition and legalization jurisdictions provided evidence on policy impacts. **International treaty implications**: The committee assessed whether current scheduling under the 1961 Single Convention adequately reflects scientific evidence or whether further rescheduling recommendations are warranted. This included evaluating whether cannabis should remain in Schedule I or move to a less restrictive category. **Equity and human rights**: For the first time, the ECDD formally considered criminal justice impacts, including incarceration rates, racial disparities in enforcement, and human rights implications of cannabis prohibition. This represented an expansion of the committee's traditional pharmacological and medical focus.

Key Players in the WHO Assessment Process

WHO Expert Committee on Drug Dependence

The ECDD comprises independent experts in pharmacology, toxicology, public health, and clinical medicine appointed by the WHO Director-General. The committee operates under the WHO's Department of Essential Medicines and Health Products. Members serve in their personal capacity rather than representing governments, though geopolitical considerations influence appointments. The 2026 committee included representatives from North America, Europe, Asia, Africa, and South America, reflecting diverse regional perspectives on cannabis policy.

UN Commission on Narcotic Drugs

The CND serves as the UN's central drug policy body, comprising 53 member states elected by the Economic and Social Council. The Commission votes on WHO scheduling recommendations, with decisions requiring a simple majority. The CND's narrow 27-25 vote in 2020 demonstrated deep divisions on cannabis policy that persist into 2026. Any new WHO recommendations will face similar political challenges regardless of scientific merit.

United Nations Office on Drugs and Crime

The UNODC provides secretariat support to the CND and implements international drug control treaties. The organization's World Drug Report series tracks global cannabis consumption trends, production estimates, and trafficking patterns. UNODC data informed the WHO's 2026 assessment, particularly regarding prevalence rates and public health indicators across member states.

International Narcotics Control Board

The INCB monitors treaty compliance and issues annual reports on member state adherence to international drug conventions. The Board has historically taken a conservative stance on cannabis reform, criticizing Uruguay, Canada, and U.S. states for treaty violations through legalization policies. INCB positions influence diplomatic negotiations surrounding WHO recommendations.

United States Government Agencies

The DEA, FDA, and National Institute on Drug Abuse provided data and testimony to the WHO review. The DEA's August 2024 proposal to reschedule cannabis to Schedule III under the Controlled Substances Act created pressure for international scheduling alignment. The FDA's approval of cannabinoid medications and ongoing clinical trial oversight informed medical application assessments. NIDA-funded research on cannabis health effects contributed substantially to the evidence base.

European Medicines Agency

The EMA's regulatory decisions on cannabis-based medicines influenced WHO therapeutic evaluations. The agency's approval of Sativex for multiple sclerosis spasticity and Epidylex for pediatric epilepsy established precedents for cannabinoid pharmaceutical development. Germany's 2024 legalization and resulting EMA oversight of medical cannabis quality standards provided regulatory models for the WHO to consider.

Cannabis Industry Organizations

Trade associations representing licensed cannabis businesses submitted comments to the WHO review. The U.S. Cannabis Council, Canadian Cannabis Council, and European Cannabis Industry Council advocated for rescheduling that would facilitate international commerce and banking access. These organizations provided market data on product safety testing, quality control standards, and economic impacts.

Medical and Scientific Societies

Professional organizations including the International Association for Cannabinoid Medicines, American Academy of Neurology, and International Association for the Study of Pain submitted evidence on therapeutic applications. The International Cannabis and Cannabinoids Institute provided research synthesis on emerging cannabinoid science. These groups emphasized evidence-based policy recommendations grounded in clinical research.

Patient Advocacy Organizations

Groups representing medical cannabis patients, including Americans for Safe Access, Epilepsy Foundation, and Multiple Sclerosis Society, testified on access barriers created by restrictive scheduling. Patient advocates emphasized the gap between scientific evidence of medical efficacy and international treaty restrictions that limit therapeutic availability in most countries.

Drug Policy Reform Organizations

The Drug Policy Alliance, Transform Drug Policy Foundation, and International Drug Policy Consortium advocated for human rights-centered approaches to cannabis regulation. These organizations presented evidence on criminal justice impacts, including incarceration rates and enforcement disparities affecting minority communities. They urged the WHO to consider social equity implications alongside pharmacological assessments.

Legal and Regulatory Framework

The WHO cannabis assessment operates within a complex international legal architecture established by three UN drug control treaties that bind 184 member states.

The 1961 Single Convention on Narcotic Drugs

The Single Convention consolidated earlier drug control treaties into a comprehensive framework governing cultivation, production, manufacture, trade, and possession of narcotic drugs. The treaty established four schedules with varying control levels. Schedule I includes substances with addiction liability and serious abuse risk, requiring the strictest controls while permitting medical and scientific use. Schedule IV, a subset of Schedule I, lists substances deemed particularly dangerous with limited or no therapeutic value. Cannabis and cannabis resin were placed in both Schedule I and Schedule IV at the Convention's inception, reflecting 1960s-era assumptions about lack of medical value. The WHO's 2019 recommendation and subsequent 2020 CND vote removed cannabis from Schedule IV while maintaining Schedule I placement. This change acknowledged medical applications while preserving international controls on cultivation and trade. Article 28 of the Single Convention permits medical and scientific cannabis use but requires licensing systems, record-keeping, and restrictions on possession and distribution. Article 36 mandates criminal penalties for unauthorized cultivation, production, and possession, though it allows alternatives to incarceration for personal use offenses. These provisions create the legal framework within which member states must operate, though interpretation and enforcement vary widely.

The 1971 Convention on Psychotropic Substances

The 1971 Convention extended international control to synthetic drugs and psychotropic substances not covered by the Single Convention. The treaty established four schedules based on abuse potential and therapeutic value. THC and its stereoisomers were placed in Schedule I, the most restrictive category. The WHO's 2019 recommendations proposed moving THC to the Single Convention framework, but the CND rejected this change in 2020. The 1971 Convention's scheduling of THC creates regulatory complications for pharmaceutical cannabinoid development. Dronabinol (synthetic THC) received Schedule II placement, allowing medical use with controls. The WHO recommended rescheduling dronabinol to Schedule III in 2019, but this proposal also failed at the CND vote.

The 1988 Convention Against Illicit Traffic

The 1988 Convention focused on drug trafficking, money laundering, and precursor chemical control. Article 3 requires parties to establish criminal offenses for cannabis cultivation, production, and distribution. Article 14 addresses measures to eradicate illicit cultivation. These provisions create legal obstacles for countries attempting to establish regulated cannabis markets, as international trafficking prohibitions technically apply even to legal domestic production. Uruguay, Canada, and U.S. states with legal cannabis markets operate in technical violation of the 1988 Convention, though enforcement mechanisms are limited. The WHO's 2026 assessment may recommend treaty amendments to accommodate regulated markets, but such changes require consensus among member states with divergent policy preferences.

U.S. Controlled Substances Act

The Controlled Substances Act of 1970 established five schedules for controlled substances, with Schedule I reserved for drugs with high abuse potential and no accepted medical use. Cannabis has remained in Schedule I since the CSA's enactment, despite state-level medical and adult-use legalization in 38 states. The DEA proposed rescheduling cannabis to Schedule III in August 2024, following a recommendation from the Department of Health and Human Services based on FDA scientific review. Schedule III placement would acknowledge medical use while maintaining DEA registration requirements for cultivation and distribution. This rescheduling would eliminate the 280E tax code restriction that prevents cannabis businesses from deducting ordinary business expenses, potentially saving the industry $1.8 billion annually. However, Schedule III cannabis would remain federally illegal for non-medical use, creating ongoing conflicts with state adult-use programs. The WHO's 2026 assessment may influence the DEA's final rescheduling decision, expected in 2027 following administrative law judge hearings and public comment periods. International scheduling recommendations provide scientific grounding for domestic policy changes, though the DEA retains independent authority under the CSA.

European Union Regulatory Framework

EU member states implement international drug treaties through national legislation while coordinating policy through the European Monitoring Centre for Drugs and Drug Addiction. The EU's approach to cannabis varies significantly by country, from the Netherlands' tolerated coffee shop system to France's strict prohibition. Germany's 2024 Cannabis Act established a regulated adult-use market within EU treaty obligations by framing legalization as a public health measure to reduce black market harms. The European Medicines Agency regulates cannabis-based medicines under the centralized authorization procedure, approving products for all EU member states. Sativex and Epidylex received EMA approval for specific medical conditions, establishing precedents for cannabinoid pharmaceutical development. The WHO's 2026 assessment may influence EMA regulatory pathways for emerging cannabinoid medicines.

Market and Business Implications

The WHO's 2026 cannabis risk assessment carries direct financial consequences for the $32 billion global legal cannabis market and the pharmaceutical industry's cannabinoid development pipeline.

Multi-State Operator Impact

U.S. multi-state operators including Curaleaf, Green Thumb Industries, Trulieve, and Cresco Labs face significant operational constraints from federal Schedule I classification. These companies operate in 20-plus states but cannot access traditional banking services, deduct business expenses under Internal Revenue Code Section 280E, or list on major U.S. stock exchanges. Many trade on Canadian exchanges or over-the-counter markets with limited liquidity. WHO recommendations supporting less restrictive international scheduling could accelerate U.S. federal rescheduling efforts, potentially unlocking institutional investment and banking access. The industry's total market capitalization of approximately $18 billion could expand substantially with normalized financial services. Analysts project that Schedule III rescheduling alone would increase MSO profitability by 15-25% through tax savings and reduced compliance costs. International MSOs face different constraints. Canadian licensed producers including Canopy Growth, Aurora Cannabis, and Tilray operate under the Cannabis Act's federal framework but face export restrictions due to international treaty obligations. WHO rescheduling recommendations that facilitate cross-border commerce could open European and Latin American markets currently inaccessible to Canadian producers.

Pharmaceutical Industry Implications

The pharmaceutical sector's cannabinoid development pipeline includes over 150 investigational drugs in various clinical trial phases. Jazz Pharmaceuticals markets Epidiolex (cannabidiol) for pediatric epilepsy, generating $800 million in annual sales. GW Pharmaceuticals' Sativex (THC/CBD combination) treats multiple sclerosis spasticity in 25 countries. AbbVie, Pfizer, and other major pharmaceutical companies have cannabinoid research programs targeting pain, inflammation, and neurological disorders. WHO recommendations on minor cannabinoids could accelerate pharmaceutical development by clarifying regulatory pathways. If the ECDD concludes that CBG, CBN, or CBC lack abuse potential and warrant exclusion from international control, pharmaceutical companies could develop these compounds without DEA Schedule I research restrictions. This regulatory clarity would reduce development costs and timelines for bringing cannabinoid medicines to market. The pharmaceutical industry has historically opposed cannabis legalization while supporting prescription cannabinoid medications. Industry lobbying groups argue that whole-plant cannabis lacks the standardization and quality control of FDA-approved pharmaceuticals. WHO assessments that distinguish between medical-grade cannabinoid medicines and recreational cannabis products align with pharmaceutical industry preferences for regulated drug development pathways.

Investment and Capital Markets

Cannabis industry investment totaled $3.2 billion in 2025, down from peak levels of $7.8 billion in 2021. Institutional investors including pension funds, insurance companies, and mutual funds largely avoid cannabis investments due to federal illegality and banking restrictions. WHO recommendations supporting international rescheduling could shift institutional investment calculus by reducing regulatory risk. Debt financing remains particularly challenging, with cannabis companies paying interest rates 10-15 percentage points above conventional business loans. Banks face federal money laundering liability under the Bank Secrecy Act for servicing cannabis businesses. The SAFE Banking Act, which would protect financial institutions serving state-legal cannabis companies, has passed the U.S. House of Representatives seven times but stalled in the Senate. WHO scientific validation of cannabis medical applications strengthens the policy case for banking reform. Private equity and venture capital investment in cannabis technology, ancillary services, and pharmaceutical development continues despite plant-touching business restrictions. Companies providing software, testing services, packaging, and cultivation equipment attracted $1.1 billion in investment during 2025. WHO assessments that reduce stigma and regulatory uncertainty could expand this ancillary investment sector.

International Trade Implications

International cannabis trade remains minimal due to treaty restrictions, with limited exceptions for pharmaceutical products and hemp. Canada exported $186 million in medical cannabis during 2025, primarily to Germany, Australia, and Israel. These exports operate under strict licensing requirements and quality standards mandated by importing countries. WHO recommendations that facilitate international commerce could unlock a global medical cannabis trade potentially worth $10-15 billion annually. Countries with established cultivation infrastructure and quality control systems, including Canada, the Netherlands, and Israel, would benefit from expanded export opportunities. Developing nations in Latin America, Africa, and Southeast Asia with favorable growing climates could enter the global supply chain. The hemp and CBD market, estimated at $5.8 billion globally, operates under different regulatory frameworks than cannabis. The WHO's 2019 footnote clarifying that CBD preparations with less than 0.2% THC are not under international control facilitated hemp-derived CBD commerce. The 2026 assessment may provide additional clarity on CBD regulatory status, potentially expanding this market segment.

What Experts Say About the 2026 Assessment

Scientific and policy experts emphasize that the WHO's 2026 cannabis reassessment must balance emerging evidence on high-potency product risks with growing data supporting therapeutic applications. Dr. Nora Volkow, director of the National Institute on Drug Abuse, has stated in congressional testimony that cannabis potency increases from an average 4% THC in 1995 to over 15% in 2025 raise concerns about dependence risk and psychiatric adverse events. NIDA-funded research demonstrates that high-potency concentrate users develop cannabis use disorder at rates 2-3 times higher than flower consumers. According to Dr. Volkow's published research, approximately 30% of regular cannabis users meet diagnostic criteria for cannabis use disorder, compared to 9% in the 1990s when potency was lower. Dr. Ziva Cooper, director of the UCLA Center for Cannabis and Cannabinoids, has published research showing that CBD and minor cannabinoids demonstrate therapeutic potential with minimal abuse liability. According to Dr. Cooper's clinical trial data, CBD reduces seizure frequency in treatment-resistant epilepsy by 40-50% and shows promise for anxiety disorders and substance use disorder treatment. Her research supports WHO conclusions that CBD warrants exclusion from international drug controls. The International Association for Cannabinoid Medicines, representing researchers and clinicians across 40 countries, submitted evidence to the WHO review documenting cannabis efficacy for chronic pain, chemotherapy-induced nausea, and multiple sclerosis spasticity. According to the organization's systematic reviews, moderate-quality evidence supports cannabis use for these conditions when conventional treatments prove inadequate. Dr. Robin Room, a professor at the University of Melbourne's Centre for Alcohol Policy Research, has written extensively on international drug treaty reform. According to Dr. Room's analysis, the 1961 Single Convention's cannabis scheduling reflects outdated assumptions about medical value and relative harms compared to other controlled substances. His research argues that cannabis causes less severe health and social harms than alcohol or tobacco, neither of which faces international control. Kevin Sabet, president of Smart Approaches to Marijuana, has testified before Congress and international bodies opposing further cannabis liberalization. According to Sabet's organization, emergency department visits for cannabis-related psychiatric episodes increased 300% in Colorado following legalization. SAM argues that WHO assessments should prioritize public health protection over commercial interests and emphasize prevention of youth access and heavy use. The Drug Policy Alliance, a reform advocacy organization, has submitted comments to WHO reviews emphasizing human rights implications of cannabis prohibition. According to DPA research, cannabis arrests in the United States disproportionately affect Black and Latino communities despite similar usage rates across racial groups. The organization argues that WHO assessments should consider criminal justice impacts alongside pharmacological evidence. Dr. Daniele Piomelli, director of the University of California Irvine Center for the Study of Cannabis, has published research on the endocannabinoid system and therapeutic cannabinoid applications. According to Dr. Piomelli's work, the human body produces endogenous cannabinoids that regulate pain, mood, appetite, and immune function. His research supports the biological plausibility of cannabis therapeutic effects and suggests that cannabinoid medicines could address conditions currently treated with opioids or benzodiazepines.

What's Next: Timeline and Decision Points

The WHO Expert Committee on Drug Dependence will publish its formal recommendations from the August 2026 review by November 2026, triggering a multi-year international policy process. Following ECDD publication, the WHO Director-General transmits recommendations to the UN Secretary-General, who forwards them to the Commission on Narcotic Drugs. The CND typically schedules votes on WHO recommendations for its annual session in March, meaning the earliest vote on 2026 recommendations would occur in March 2027. The CND vote requires a simple majority of the 53 member states. Given the narrow 27-25 margin in December 2020, any controversial recommendations face uncertain prospects. Diplomatic negotiations during the months between WHO publication and the CND vote will determine whether recommendations gain sufficient support. The United States, European Union members, Canada, and Mexico typically support science-based scheduling, while Russia, China, and several Middle Eastern and Asian nations oppose liberalization. If the CND approves WHO recommendations, member states must implement treaty changes through domestic legislation. This process varies by country, with some nations requiring parliamentary approval and others allowing executive action. Implementation timelines range from months to years depending on legislative calendars and political priorities. The DEA's cannabis rescheduling process operates on a parallel timeline. Following the August 2024 Notice of Proposed Rulemaking to move cannabis to Schedule III, the agency must conduct administrative law judge hearings, review public comments, and issue a final rule. This process typically requires 18-36 months, suggesting a final decision in 2026 or 2027. WHO recommendations published in November 2026 could influence the DEA's final determination if the agency has not yet issued its rule. State-level cannabis policy will continue evolving regardless of international scheduling decisions. Ballot initiatives for adult-use legalization are expected in Florida, Ohio, and Pennsylvania during 2026-2027 election cycles. State legislatures in New York, Illinois, and New Jersey continue refining implementation of existing legalization laws. These state-level developments create pressure for federal policy alignment. The pharmaceutical industry's cannabinoid development pipeline will advance based on FDA regulatory decisions rather than international scheduling. Clinical trials for cannabinoid medicines targeting PTSD, chronic pain, and neurodegenerative diseases are expected to produce results during 2027-2028. FDA approval decisions for these investigational drugs could expand medical cannabis acceptance and influence future WHO assessments. International legalization efforts in Germany, Thailand, Czech Republic, and other countries will generate additional real-world data on public health outcomes, market structures, and regulatory approaches. The WHO typically conducts comprehensive substance reviews every 5-10 years, suggesting the next full cannabis assessment would occur around 2031-2036. However, emerging evidence on specific issues such as high-potency products or synthetic cannabinoids could trigger interim reviews.

Further Reading and Primary Sources

• World Health Organization Expert Committee on Drug Dependence: Critical Review of Cannabis and Cannabis Resin (2018) - https://www.who.int/medicines/access/controlled-substances/ecdd_40_meeting/en/
• World Health Organization: WHO recommendations on cannabis and cannabis-related substances (2019) - https://www.who.int/medicines/access/controlled-substances/WHORecommendation5.1_cannabis.pdf
• United Nations Commission on Narcotic Drugs: Voting Record on WHO Cannabis Recommendations (December 2, 2020) - https://www.unodc.org/unodc/en/commissions/CND/session/63_Session_2020/session-63-of-the-commission-on-narcotic-drugs.html
• 1961 Single Convention on Narcotic Drugs - https://www.unodc.org/pdf/convention_1961_en.pdf
• 1971 Convention on Psychotropic Substances - https://www.unodc.org/pdf/convention_1971_en.pdf
• 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances - https://www.unodc.org/pdf/convention_1988_en.pdf
• U.S. Drug Enforcement Administration: Notice of Proposed Rulemaking on Cannabis Rescheduling (August 2024) - https://www.federalregister.gov/
• U.S. Food and Drug Administration: Cannabis and Cannabis-Derived Compounds - https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products
• National Institute on Drug Abuse: Cannabis (Marijuana) Research Report - https://nida.nih.gov/research-topics/cannabis-marijuana
• European Medicines Agency: Epidyolex (cannabidiol) Authorization Details - https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex
• International Narcotics Control Board: Annual Report 2025 - https://www.incb.org/incb/en/publications/annual-reports/annual-report-2025.html
• United Nations Office on Drugs and Crime: World Drug Report 2026 - https://www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2026.html
• Canadian Cannabis Act (S.C. 2018, c. 16) - https://laws-lois.justice.gc.ca/eng/acts/C-24.5/
• Germany Cannabis Act (CanG) 2024 - https://www.bundesgesundheitsministerium.de/
• Controlled Substances Act, 21 U.S.C. § 812 - https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13-subchapI-partB-sec812.pdf